A BridgeBio Pharma drug developed for an increasingly prevalent cardiovascular condition has won FDA approval, marking a comeback for a company and a molecule with a turbulent history. But BridgeBio’s ...
- Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date: - In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related ...
Clinical Trials Arena on MSN
BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial
An indirect comparison highlights Attruby’s potential as the better TTR stabiliser over Pfizer’s tafamidis in frontline ATTR-CM.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results